Direct Healthcare Professional Communication on supply and safety concerns for CAELYX® (pegylated liposomal doxorubicin) 20 mg vials for injection

Janssen (Singapore) would like to update healthcare professionals on the CAELYX® supply shortages due to production difficulties at our specialty contract drug manufacturer's site, Ben Venue Laboratories (BVL), USA, following a potential risk of batch contamination due to the deficiencies in sterility assurance in quality management. The advisory to healthcare professionals include that existing CAELYX® stocks should only be used to complete treatment that has been initiated and no new patients should be initiated on CAELYX® treatment, until further notice. In addition, physicians may also wish to consider other treatment alternatives.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.